The cyclin D:CDK4/6 complex is a factor that promotes breast cancer progression [22, 23], and CDK4/6 inhibitors have recently been administered to patients with unresectable or recurrent Luminal breast cancer [24, 25]. Here, CDK4 is linked to breast cancer.